Search research articles
Contact Us
Filters
Showing results (21-30 of 29) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 29 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 15, 2023
Preclinical Characterization of AZD9574, a Blood-Brain Barrier Penetrant Inhibitor of PARP1
Anna D Staniszewska, Domenic Pilger, Sonja J Gill, et al.
Bioorganic & Medicinal Chemistry Letters
|
October 15, 2017
Highly potent and selective Na<sub>V</sub>1.7 inhibitors for use as intravenous agents and chemical probes
R Ian Storer, Andy Pike, Nigel A Swain, et al.
Journal of Medicinal Chemistry
|
January 30, 2026
Discovery of AZD9750, an Orally Bioavailable Androgen Receptor Degrader for the Treatment of Prostate Cancer
James S Scott, Laura Evans, Peter C Astles, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 3, 2023
Optimization of a series of novel, potent and selective Macrocyclic SYK inhibitors
Neil P Grimster, Lakshmaiah Gingipalli, Amber Balazs, et al.
Bioorganic & Medicinal Chemistry Letters
|
July 28, 2020
Optimization of a series of potent, selective and orally bioavailable SYK inhibitors
Neil P Grimster, Lakshmaiah Gingipalli, Bernard Barlaam, et al.
Journal of Medicinal Chemistry
|
December 11, 2020
Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies
Bernard Barlaam, Robert Casella, Justin Cidado, et al.
Journal of Medicinal Chemistry
|
July 7, 2017
Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of Na<sub>V</sub>1.7
Nigel A Swain, Dave Batchelor, Serge Beaudoin, et al.
Nature Communications
|
March 25, 2026
A dihydrouracil CRBN ligand mitigates IMiD associated safety liabilities in heterobifunctional targeted protein degrader
Monica C Rodrigo-Brenni, Jasper C Komen, Ghaith M Hamza, et al.
Journal of Medicinal Chemistry
|
December 10, 2024
Discovery of 6-Fluoro-5-{4-[(5-fluoro-2-methyl-3-oxo-3,4-dihydroquinoxalin-6-yl)methyl]piperazin-1-yl}-<i>N</i>-methylpyridine-2-carboxamide (AZD9574): A CNS-Penetrant, PARP1-Selective Inhibitor
Jeffrey W Johannes, Amber Y S Balazs, Derek Barratt, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 29) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 29 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 15, 2023
Preclinical Characterization of AZD9574, a Blood-Brain Barrier Penetrant Inhibitor of PARP1
Anna D Staniszewska, Domenic Pilger, Sonja J Gill, et al.
Bioorganic & Medicinal Chemistry Letters
|
October 15, 2017
Highly potent and selective Na<sub>V</sub>1.7 inhibitors for use as intravenous agents and chemical probes
R Ian Storer, Andy Pike, Nigel A Swain, et al.
Journal of Medicinal Chemistry
|
January 30, 2026
Discovery of AZD9750, an Orally Bioavailable Androgen Receptor Degrader for the Treatment of Prostate Cancer
James S Scott, Laura Evans, Peter C Astles, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 3, 2023
Optimization of a series of novel, potent and selective Macrocyclic SYK inhibitors
Neil P Grimster, Lakshmaiah Gingipalli, Amber Balazs, et al.
Bioorganic & Medicinal Chemistry Letters
|
July 28, 2020
Optimization of a series of potent, selective and orally bioavailable SYK inhibitors
Neil P Grimster, Lakshmaiah Gingipalli, Bernard Barlaam, et al.
Journal of Medicinal Chemistry
|
December 11, 2020
Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies
Bernard Barlaam, Robert Casella, Justin Cidado, et al.
Journal of Medicinal Chemistry
|
July 7, 2017
Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of Na<sub>V</sub>1.7
Nigel A Swain, Dave Batchelor, Serge Beaudoin, et al.
Nature Communications
|
March 25, 2026
A dihydrouracil CRBN ligand mitigates IMiD associated safety liabilities in heterobifunctional targeted protein degrader
Monica C Rodrigo-Brenni, Jasper C Komen, Ghaith M Hamza, et al.
Journal of Medicinal Chemistry
|
December 10, 2024
Discovery of 6-Fluoro-5-{4-[(5-fluoro-2-methyl-3-oxo-3,4-dihydroquinoxalin-6-yl)methyl]piperazin-1-yl}-<i>N</i>-methylpyridine-2-carboxamide (AZD9574): A CNS-Penetrant, PARP1-Selective Inhibitor
Jeffrey W Johannes, Amber Y S Balazs, Derek Barratt, et al.
Page
of 3